Addex Therapeutics (0QNV) Ratios
Addex Therapeutics Ratios
GB:0QNV's free cash flow for Q2 2026 was $-469.76K. For the 2026 fiscal year, GB:0QNV's free cash flow was decreased by $-5.00 and operating cash flow was $-469.75K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.40 | 4.41 | 1.46 | 2.39 | 5.31 |
| Quick Ratio | 1.40 | 4.41 | 1.46 | 2.39 | 5.31 |
| Cash Ratio | 1.37 | 4.17 | 1.34 | 2.12 | 4.95 |
| Solvency Ratio | -4.21 | 7.31 | -2.93 | -6.08 | -2.69 |
| Operating Cash Flow Ratio | -1.81 | -6.70 | -2.76 | -5.01 | -3.56 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -735.51 | -29.17 | -57.45 | -51.11 |
| Net Current Asset Value | $ 77.41K | $ 2.53M | $ 738.18K | $ 4.46M | $ 16.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.07 | 0.05 | 0.02 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.30 | 0.08 | 0.03 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.23 | 0.07 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.34 | 1.10 | 4.05 | 1.69 | 1.33 |
| Debt Service Coverage Ratio | -175.94 | -428.05 | -34.70 | -61.78 | -42.78 |
| Interest Coverage Ratio | -175.94 | -776.78 | -103.81 | -419.66 | -246.08 |
| Debt to Market Cap | 0.00 | 0.00 | 0.08 | 0.06 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Net Debt to EBITDA | 0.57 | 0.71 | 0.34 | 0.32 | 1.34 |
| Profitability Margins | |||||
| Gross Profit Margin | 95.02% | -108.35% | -329.72% | -928.06% | -331.42% |
| EBIT Margin | -1627.17% | -1196.41% | -653.13% | -1459.14% | -524.26% |
| EBITDA Margin | -1627.17% | -1132.98% | -635.85% | -1436.42% | -512.34% |
| Operating Profit Margin | -1627.17% | -671.94% | -139.06% | -1442.61% | -531.70% |
| Pretax Profit Margin | -3955.25% | -1197.28% | -155.00% | -1462.57% | -526.42% |
| Net Profit Margin | -3889.60% | 1720.75% | -654.47% | -1462.57% | -528.58% |
| Continuous Operations Profit Margin | -3955.25% | -1197.28% | -155.00% | -1462.57% | -526.42% |
| Net Income Per EBT | 98.34% | -143.72% | 422.22% | 100.00% | 100.41% |
| EBT Per EBIT | 243.08% | 178.18% | 111.47% | 101.38% | 99.01% |
| Return on Assets (ROA) | -105.82% | 66.12% | -227.41% | -251.20% | -68.38% |
| Return on Equity (ROE) | -141.32% | 72.96% | -921.57% | -423.46% | -91.05% |
| Return on Capital Employed (ROCE) | -54.55% | -27.92% | -128.27% | -410.41% | -84.24% |
| Return on Invested Capital (ROIC) | -54.47% | -27.87% | -97.67% | -368.26% | -81.69% |
| Return on Tangible Assets | -105.82% | 66.12% | -227.41% | -251.20% | -68.38% |
| Earnings Yield | -108.30% | 125.73% | -308.83% | -457.68% | -43.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.61 | 26.43 | 10.66 | 2.38 | 8.99 |
| Payables Turnover | 0.01 | 3.37 | 7.04 | 11.46 | 7.17 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 5.05 | 9.60 | 4.57 | 3.57 | 5.38 |
| Asset Turnover | 0.03 | 0.04 | 0.35 | 0.17 | 0.13 |
| Working Capital Turnover Ratio | 0.11 | 0.20 | 0.55 | 0.13 | 0.17 |
| Cash Conversion Cycle | -25932.46 | -94.41 | -17.61 | 121.67 | -10.29 |
| Days of Sales Outstanding | 42.38 | 13.81 | 34.23 | 153.53 | 40.60 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 25974.84 | 108.22 | 51.84 | 31.86 | 50.89 |
| Operating Cycle | 42.38 | 13.81 | 34.23 | 153.53 | 40.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.05 | -0.11 | -0.36 | -0.43 |
| Free Cash Flow Per Share | -0.02 | -0.05 | -0.11 | -0.36 | -0.43 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -4224.53 | -1168.14 | -28291.20 | -466.11 |
| Capital Expenditure Coverage Ratio | 0.00 | -4224.53 | -1168.14 | -28291.20 | -466.11 |
| Operating Cash Flow Coverage Ratio | -62.66 | -127.96 | -23.21 | -44.05 | -30.51 |
| Operating Cash Flow to Sales Ratio | -12.56 | -13.11 | -4.96 | -11.56 | -5.04 |
| Free Cash Flow Yield | -34.98% | -95.77% | -234.02% | -361.62% | -41.53% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.92 | 0.80 | -0.32 | -0.22 | -2.30 |
| Price-to-Sales (P/S) Ratio | 35.91 | 13.69 | 2.12 | 3.20 | 12.17 |
| Price-to-Book (P/B) Ratio | 1.30 | 0.58 | 2.98 | 0.93 | 2.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.86 | -1.04 | -0.43 | -0.28 | -2.41 |
| Price-to-Operating Cash Flow Ratio | -2.86 | -1.04 | -0.43 | -0.28 | -2.41 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.01 | 0.00 | -0.10 | 0.37 |
| Enterprise Value Multiple | -1.64 | -0.50 | 0.01 | 0.10 | -1.04 |
| Enterprise Value | 4.61M | 2.31M | -102.99K | -2.04M | 15.48M |
| EV to EBITDA | -1.64 | -0.50 | 0.01 | 0.10 | -1.04 |
| EV to Sales | 26.64 | 5.64 | -0.06 | -1.43 | 5.31 |
| EV to Free Cash Flow | -2.12 | -0.43 | 0.01 | 0.12 | -1.05 |
| EV to Operating Cash Flow | -2.12 | -0.43 | 0.01 | 0.12 | -1.05 |
| Tangible Book Value Per Share | 0.04 | 0.10 | 0.02 | 0.11 | 0.50 |
| Shareholders’ Equity Per Share | 0.04 | 0.10 | 0.02 | 0.11 | 0.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.01 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.02 | 0.03 | 0.09 |
| Net Income Per Share | -0.06 | 0.07 | -0.14 | -0.46 | -0.45 |
| Tax Burden | 0.98 | -1.44 | 4.22 | 1.00 | 1.00 |
| Interest Burden | 2.43 | 1.00 | 0.24 | 1.00 | 1.00 |
| Research & Development to Revenue | 3.88 | 1.45 | 0.61 | 10.31 | 4.40 |
| SG&A to Revenue | 10.91 | 5.63 | 4.47 | 5.13 | 1.76 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 2.59 | 0.40 |
| Income Quality | 0.32 | 1.09 | 0.76 | 0.79 | 0.96 |
Currency in CHF